GlobeNewswire Inc.··Biomea Fusion, Inc.Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose
Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes